Estrella Immunopharma, Inc.
ESLA- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001844417
No open-market purchases or sales by Estrella Immunopharma, Inc. insiders were filed in the last 90 days; 15 institutions reported holding it in 13F filings for Q2 2026, worth $4.99M in total; no superinvestor holds it.
Other share classesESLAW
Q4 2025 vs. Q3 2025
How the institutions holding Estrella Immunopharma, Inc. changed between Q3 2025 and Q4 2025.
All holders in Q4 2025All holders in Q3 2025
| Measure | Q3 2025 | Of which not filed for Q4 2025 | Q4 2025 | Change |
|---|---|---|---|---|
| Holders | 13 | 2 | 15 | +4 |
| Shares | 743.2K | 50.0K | 999.6K | +306.4K (+44.2%) |
| Value | $878.8K | $57.5K | $1.56M | +$737.8K (+89.8%) |
2 institutions that held it in Q3 2025 haven't filed for Q4 2025 yet. Not filing isn't selling, so the changes leave them out.
New holders (6)
Institutions that held Estrella Immunopharma, Inc. at the end of Q4 2025 but not at the end of Q3 2025.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Marshall Wace, LLP | 56,236 | $87.7K | 0.00% |
| Quadrature Capital Ltd | 27,781 | $43.3K | 0.00% |
| Northern Trust Corp | 19,624 | $30.6K | 0.00% |
| Morgan Stanley | 11,097 | $17.3K | 0.00% |
| Jane Street Group, LLC | 10,441 | $16.3K | 0.00% |
| Royal Bank of Canada | 6,600 | $10.0K | 0.00% |
Sold out (2)
Institutions that held Estrella Immunopharma, Inc. at the end of Q3 2025 and filed for Q4 2025 without it.
| Institution | Shares, Q3 2025 | Value, Q3 2025 |
|---|---|---|
| Tower Research Capital LLC (TRC) | 4,015 | $4.62K |
| SBI Securities Co., Ltd. | 1 | $1 |
Not filed for Q4 2025 yet (2)
Institutions that held Estrella Immunopharma, Inc. at the end of Q3 2025 and haven't filed a 13F for Q4 2025. Not filing isn't selling, so they aren't counted as sold out.
| Institution | Shares, Q3 2025 | Value, Q3 2025 |
|---|---|---|
| Atw Spac Management LLC | 40,000 | $46.0K |
| Maso Capital Partners Ltd | 10,000 | $11.5K |